AWAK Attracts Investment Billions
Singapore-based AWAK Technologies’ miniaturized sorbent platform for PD and HD regenerates dialysate to use up to 90% less fluid. This package was intriguing enough to attract an $11.2B investment from Accuron MedTech—improving its changes of reaching the market!
Read the full article » | Posted 06-12-2017
Related Articles
- The Lancet Digital Health published results of Humacyte’s Phase III clinical trial of its V007 acellular tissue engineered vessel (ATEV) HD access Posted 09-18-2026
- Humacyte, Inc. announced Robert J. Kossman, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN have joined the company as advisors. Posted 08-21-2026
- Byonyks on the Move: X-2 and X-3 APD Devices in Development Posted 07-16-2026
- Dr. Ben Reynolds and the Virtual Reality Kidney Dialysis Training Project Posted 06-17-2026